Beyond Air Q1 FY2024 revenue $0.1M (first commercial); net loss $14.1M; secured $40M debt facility

Beyond Air, Inc.

2024-Q1 EPS reported -$0.45 revenue$59,000

Revenue of $0.1M from commercial LungFit PH sales; cost of revenue $0.3M.
Net loss $14.1M ($0.45 loss per share) vs $10.9M ($0.37) YoY; R&D $4.7M, G&A $10.9M.
Secured up to $40M debt financing from Avenue Capital; $17.5M drawn; cash $57M.
In excess of $1M annual commercial LungFit PH contracts; CE Mark expected by end 2023.
Agreed with FDA on VCAP study for 2023-24 winter; added nNOS program for autism.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beyond Air, Inc. reported the fiscal quarter ended June 30, 2023 results: revenue $0.1 million, net income ($14.1) million, EPS ($0.45) per share, basic and diluted.

Period: the fiscal quarter ended June 30, 2023
Revenue: $0.1 million
Net income: ($14.1) million
EPS: ($0.45) per share, basic and diluted
Result: reported results

Exact text from the filing

a first-in-human study of nNOS for treatment of ASD in 2025 Financial Results for the Fiscal Quarter Ended June 30, 2023 Revenues for the three months ended June 30, 2023 were $0.1 million compared to zero for the quarter ended June 30, 2022. Cost of revenue of $0.3 million was recognized for the three months ended June 30, 2023, compared to $0 for the three months

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Beyond Air, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-028715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.